KR101290437B1 - 글루코키나제 활성화제로서 유용한 아릴시클로프로필아세트아미드 유도체 - Google Patents

글루코키나제 활성화제로서 유용한 아릴시클로프로필아세트아미드 유도체 Download PDF

Info

Publication number
KR101290437B1
KR101290437B1 KR1020117014073A KR20117014073A KR101290437B1 KR 101290437 B1 KR101290437 B1 KR 101290437B1 KR 1020117014073 A KR1020117014073 A KR 1020117014073A KR 20117014073 A KR20117014073 A KR 20117014073A KR 101290437 B1 KR101290437 B1 KR 101290437B1
Authority
KR
South Korea
Prior art keywords
solution
compound
diabetes
added
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020117014073A
Other languages
English (en)
Korean (ko)
Other versions
KR20110086751A (ko
Inventor
아나 벨렌 부에노 멜렌도
프란시스코 하비에르 아제하스-치차로
Original Assignee
일라이 릴리 앤드 캄파니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 일라이 릴리 앤드 캄파니 filed Critical 일라이 릴리 앤드 캄파니
Publication of KR20110086751A publication Critical patent/KR20110086751A/ko
Application granted granted Critical
Publication of KR101290437B1 publication Critical patent/KR101290437B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/44—Acylated amino or imino radicals
    • C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
KR1020117014073A 2008-12-19 2009-12-11 글루코키나제 활성화제로서 유용한 아릴시클로프로필아세트아미드 유도체 Expired - Fee Related KR101290437B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP08380341.1 2008-12-19
EP08380341 2008-12-19
US15378109P 2009-02-19 2009-02-19
US61/153,781 2009-02-19
PCT/US2009/067603 WO2010080333A1 (en) 2008-12-19 2009-12-11 Arylcyclopropylacetamide derivatives useful as glucokinase activators

Publications (2)

Publication Number Publication Date
KR20110086751A KR20110086751A (ko) 2011-07-29
KR101290437B1 true KR101290437B1 (ko) 2013-07-29

Family

ID=40545955

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020117014073A Expired - Fee Related KR101290437B1 (ko) 2008-12-19 2009-12-11 글루코키나제 활성화제로서 유용한 아릴시클로프로필아세트아미드 유도체

Country Status (34)

Country Link
US (1) US8063079B2 (https=)
EP (1) EP2379517B1 (https=)
JP (1) JP5497064B2 (https=)
KR (1) KR101290437B1 (https=)
CN (1) CN102256952B (https=)
AR (1) AR074470A1 (https=)
AU (1) AU2009335931B2 (https=)
BR (1) BRPI0923183B1 (https=)
CA (1) CA2746746C (https=)
CO (1) CO6382120A2 (https=)
CR (1) CR20110342A (https=)
DK (1) DK2379517T3 (https=)
DO (1) DOP2011000197A (https=)
EA (1) EA019055B1 (https=)
EC (1) ECSP11011150A (https=)
ES (1) ES2435242T3 (https=)
HR (1) HRP20130983T1 (https=)
IL (1) IL213210A (https=)
JO (1) JO2979B1 (https=)
MA (1) MA32902B1 (https=)
MX (1) MX2011006434A (https=)
MY (1) MY180567A (https=)
NZ (1) NZ592930A (https=)
PA (1) PA8851901A1 (https=)
PE (1) PE20120339A1 (https=)
PL (1) PL2379517T3 (https=)
PT (1) PT2379517E (https=)
SG (1) SG172256A1 (https=)
SI (1) SI2379517T1 (https=)
TN (1) TN2011000294A1 (https=)
TW (1) TWI395748B (https=)
UA (1) UA104742C2 (https=)
WO (1) WO2010080333A1 (https=)
ZA (1) ZA201103944B (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102959076B (zh) 2010-03-31 2015-09-16 斯克里普斯研究所 重编程细胞
CN105899192B (zh) 2013-11-22 2019-08-13 国立大学法人东京大学 药物递送用载体、偶联物及含有这些成分的组合物以及它们的施予方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004063179A1 (en) 2003-01-06 2004-07-29 Eli Lilly And Company Substituted arylcyclopropylacetamides as glucokinase activators
WO2007051847A1 (en) 2005-11-03 2007-05-10 Prosidion Ltd Tricyclo substituted amides as glucokinase modulators

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA02010745A (es) 2000-05-03 2003-03-10 Hoffmann La Roche Activadores de glucocinasa heteroaromaticos de alquinil-fenilo.
DK1282611T3 (da) 2000-05-08 2005-02-14 Hoffmann La Roche Substituerede phenylacetatamider og anvendelse deraf som glucokinaseaktivatorer
WO2001085707A1 (en) 2000-05-08 2001-11-15 F. Hoffmann-La Roche Ag Para-amine substituted phenylamide glucokinase activators
MY141521A (en) * 2002-12-12 2010-05-14 Hoffmann La Roche 5-substituted-six-membered heteroaromatic glucokinase activators
PL378117A1 (pl) 2003-02-11 2006-03-06 Prosidion Limited Tricyklopodstawione związki amidowe
US7262196B2 (en) 2003-02-11 2007-08-28 Prosidion Limited Tri(cyclo) substituted amide glucokinase activator compounds
US7432287B2 (en) * 2003-02-26 2008-10-07 Banyu Pharmeceutical Co., Ltd. Heteroarylcarbamoylbenzene derivative
MXPA06012008A (es) 2004-04-21 2007-01-25 Prosidion Ltd Compuestos de amida tri(ciclo) sustituidos.
KR100890695B1 (ko) 2004-08-12 2009-03-26 프로시디온 리미티드 치환된 페닐아세트아미드 및 글루코키나제 활성화제로서의그의 용도
EP1824835A1 (en) * 2004-12-03 2007-08-29 Novo Nordisk A/S Heteroaromatic glucokinase activators
RU2008103142A (ru) * 2005-07-01 2009-08-10 Новартис АГ (CH) Комбинация органических соединений
JP4033409B1 (ja) 2005-07-11 2008-01-16 田辺三菱製薬株式会社 オキシム誘導体及びその製法
JP2009504621A (ja) * 2005-08-09 2009-02-05 アストラゼネカ アクチボラグ 糖尿病の処置のためのヘテロアリールカルバモイルベンゼン誘導体
WO2007051845A1 (en) 2005-11-03 2007-05-10 Prosidion Ltd Tricyclo substituted amides
WO2007051846A1 (en) 2005-11-03 2007-05-10 Prosidion Ltd Tricyclo substituted amides
KR20090025358A (ko) * 2006-07-24 2009-03-10 에프. 호프만-라 로슈 아게 글루코키나제 활성화제로서의 피라졸
EP2105435A4 (en) * 2007-01-10 2011-06-15 Mitsubishi Tanabe Pharma Corp Hydrazone derivative
KR101608259B1 (ko) 2008-04-28 2016-04-01 교린 세이야꾸 가부시키 가이샤 시클로펜틸아크릴산아미드 유도체

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004063179A1 (en) 2003-01-06 2004-07-29 Eli Lilly And Company Substituted arylcyclopropylacetamides as glucokinase activators
WO2007051847A1 (en) 2005-11-03 2007-05-10 Prosidion Ltd Tricyclo substituted amides as glucokinase modulators

Also Published As

Publication number Publication date
JO2979B1 (en) 2016-03-15
BRPI0923183B1 (pt) 2019-03-19
CA2746746C (en) 2013-09-24
IL213210A (en) 2015-03-31
BRPI0923183A2 (pt) 2016-02-16
AR074470A1 (es) 2011-01-19
ZA201103944B (en) 2012-11-28
AU2009335931B2 (en) 2012-05-31
JP5497064B2 (ja) 2014-05-21
WO2010080333A1 (en) 2010-07-15
DOP2011000197A (es) 2011-09-15
JP2012512874A (ja) 2012-06-07
ES2435242T3 (es) 2013-12-17
BRPI0923183A8 (pt) 2017-09-12
IL213210A0 (en) 2011-07-31
TN2011000294A1 (en) 2012-12-17
US8063079B2 (en) 2011-11-22
EP2379517B1 (en) 2013-08-28
PA8851901A1 (es) 2010-07-27
TWI395748B (zh) 2013-05-11
PL2379517T3 (pl) 2014-01-31
MA32902B1 (fr) 2011-12-01
CN102256952A (zh) 2011-11-23
SI2379517T1 (sl) 2013-10-30
SG172256A1 (en) 2011-07-28
CN102256952B (zh) 2013-12-11
TW201029999A (en) 2010-08-16
NZ592930A (en) 2013-01-25
DK2379517T3 (da) 2013-09-30
CO6382120A2 (es) 2012-02-15
KR20110086751A (ko) 2011-07-29
HRP20130983T1 (hr) 2013-11-22
PT2379517E (pt) 2013-11-21
MY180567A (en) 2020-12-02
EA019055B1 (ru) 2013-12-30
EA201170845A1 (ru) 2011-12-30
US20100160395A1 (en) 2010-06-24
AU2009335931A1 (en) 2011-07-07
CA2746746A1 (en) 2010-07-15
ECSP11011150A (es) 2011-07-29
PE20120339A1 (es) 2012-04-16
EP2379517A1 (en) 2011-10-26
UA104742C2 (uk) 2014-03-11
CR20110342A (es) 2011-09-14
MX2011006434A (es) 2011-07-19

Similar Documents

Publication Publication Date Title
USRE50050E1 (en) Pyrimidinedione compounds
EP3130583B1 (en) Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
CA2904985C (en) Pyrazole-amide compound and medicinal uses therefor
CN104039774A (zh) Hcv ns3蛋白酶抑制剂
US20150018403A1 (en) Fluorene-amide compounds and pharmaceutical use thereof
CN103328466A (zh) Hcv ns3蛋白酶抑制剂
KR101290437B1 (ko) 글루코키나제 활성화제로서 유용한 아릴시클로프로필아세트아미드 유도체
US20150025120A1 (en) Pyrazole-alcohol compounds and pharmaceutical use thereof
EP4010324B1 (en) Pyrimidine-5-carboxamide compound
US20240277639A1 (en) Vanin-1 inhibitor
HK1159635B (en) Arylcyclopropylacetamide derivatives useful as glucokinase activators
HK1159635A (en) Arylcyclopropylacetamide derivatives useful as glucokinase activators
US7304057B2 (en) Substituted 6-membered N-heterocyclic compounds and method for their use as neurological regulator
KR20060031956A (ko) ｐ90 리보솜 Ｓ6 키나제 1 (ＲＳＫ1)의 직접적인 키나제활성증진을 통한 간섬유화와 간경변증 예방 및 치료용약학조성물

Legal Events

Date Code Title Description
A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

FPAY Annual fee payment

Payment date: 20160629

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

FPAY Annual fee payment

Payment date: 20170629

Year of fee payment: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

FPAY Annual fee payment

Payment date: 20180628

Year of fee payment: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

FPAY Annual fee payment

Payment date: 20190624

Year of fee payment: 7

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20200723

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20200723